cm355
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 16, 2021 (NCT05210868)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07104344 | N/A | Sep 25, 2025 | Central South University |
| NCT05210868 | Phase 1/Phase 2 (Phase 2) | Nov 16, 2021 | Beijing InnoCare Pharma Tech Co., Ltd., Government of China |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing InnoCare Pharma Tech Co., Ltd. | For profit | 1 | 1 | 1 | 2021 |
| Central South University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Government of China | Government | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1